# Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

> **NCT03028350** · PHASE2 · COMPLETED · sponsor: **Cumberland Pharmaceuticals** · enrollment: 54 (actual)

## Conditions studied

- Asthma, Aspirin-Induced

## Interventions

- **DRUG:** Ifetroban Oral Capsule
- **DRUG:** Placebo Oral Capsule

## Key facts

- **NCT ID:** NCT03028350
- **Lead sponsor:** Cumberland Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-17
- **Primary completion:** 2023-04-25
- **Final completion:** 2023-04-25
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03028350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03028350, "Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03028350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*